Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)

PURPOSE: Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies delay relapse and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Seckl, Michael J., Ottensmeier, Christian H., Cullen, Michael, Schmid, Peter, Ngai, Yenting, Muthukumar, Dakshinamoorthy, Thompson, Joyce, Harden, Susan, Middleton, Gary, Fife, Kate M., Crosse, Barbara, Taylor, Paul, Nash, Stephen, Hackshaw, Allan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/
https://www.ncbi.nlm.nih.gov/pubmed/28240967
http://dx.doi.org/10.1200/JCO.2016.69.7391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455702/
https://www.ncbi.nlm.nih.gov/pubmed/28240967
http://dx.doi.org/10.1200/JCO.2016.69.7391

Ejemplares similares